A number of gene therapies are in late-stage clinical trials and expected to reach the market in the next several years.PAP-Q4-17-CL-002
Keeping up with quality is key for the industry throughout the supply chain. Quality must be ensured from the earliest phases of development.PAP-Q4-17-FA-001
The (bio)pharmaceutical industry is becoming a high-technology sector with success directly linked to innovation.PAP-Q4-17-NO-001
Lack of effective management of the outbound distribution of clinical trial materials can negatively impact study outcomes.PAP-Q4-17-CL-001
The contract manufacturing market for antibody-drug conjugates has huge potential, but an extraordinary range of capabilities is essential to be in the game.PAP-Q04-17-VP-001
Efficient development of optimal routes and manufacturing processes for the production of increasingly complex small molecule APIs requires extensive expertise.PAP-Q4-17-CL-003
Following a string of approvals, biosimilars are positioned to go the way of generics.PAP-Q4-17-FA-002
Call it the automation of everything — a hands-off approach will permeate supply chains in the near future.PAP-Q4-17-FA-003
Potassium channels are present in nearly all types of cells and involved in most physiological functions.PAP-Q4-17-CL-004
Reducing the time, cost and environmental footprint of manufacturing processes continues to be a major driver of technology development.PAP-Q3-17-CL-003
Single-use technologies (SUTs) have introduced a broad range of cost and operating efficiencies to bioprocessing operations.PAP-Q4-17-CL-006
Anticipating 2018 technologies and their impact.PAP-Q4-17-RT-002
Q: What do you see as being the most innovative technologies introduced in 2017? Why were they important? What impacts did they have?
The importance and impact on innovative technologies introduced in 2017.PAP-Q4-17-RT-001
Right-First-Time Innovation Approach Drives Continual Investment
Adam Kujath, Site Director at Alcami discusses implementing a right-first-time approach for optimum results.
Charles River Expands CRISPR Offerings with Second License
Company can now support customers with CRISPR/Cas9 technology from the Broad Institute and ERS Genomics.
Mitigating Shortages of Injectable Drugs in the United States
Marga Viñes, Business Development Manager at Grifols explains how to tackle drug shortages.
Fucoidans Found in Seaweed Exhibit Promising Anticancer Properties
Tumor growth rates for certain cancers were reduced in different animal models.
Novo Nordisk Bags FDA Approval for New Diabetes Treatment
Ozempic will compete with Trulicity (Eli Lilly & Co.) and Bydureo (AstraZeneca).
New FDA Draft Guidance Intended to Accelerate Development of Drugs for Rare Pediatric Diseases
Fewer patients may be needed for some clinical trials, and other trials may be eliminated.
No Clinically Meaningful Difference: The Upward Trend of Biosimilars
Following a string of approvals, biosimilars are positioned to go the way of generics.
Looking forward, what technologies do you anticipate having the greatest impact in 2018?
Experts weigh in on our Roundtable question.
Moving Beyond Monoclonal Antibodies
Next-generation antibody therapeutics are designed to provide improved specificity, efficacy and safety when compared to conventional monoclonal antibodies.
Pharma’s Automation Index on the Rise
Call it the automation of everything — a hands-off approach will permeate supply chains in the near future.
Segregation in the Design of Gene Therapy Manufacturing Facilities
Peter Walters, Lead Process Engineer for CRB USA explains segregating manufacturing operations.
Phase III Study Confirms AbbVie Leukemia Combo Meets Endpoint
Open-label, randomized study demonstrates VENCLEXTA™/VENCLYXTO™ safety and efficacy.
Flexible Partnership, Inflexible Quality
Driven by the demand for biologics, most of which still require parenteral administration, the sterile injectable market is projected to continue its 6% annual growth through 2020.
Aprecia and Cycle Team to Develop 3D-Printed Orphan Drugs
Proprietary ZipDose technology creates patient-friendly rapidly disintegrating oral forms.
First “Follow-On” Insulin Product Approved
FDA green lights Admelog to treat both type 1 and 2 diabetes.
Developing Targeted Potassium Channel Openers for CNS-Related Therapeutics
Doug Krafte, Ph.D., Chief Scientific Officer, Neil Castle, Ph.D.
Vice President of Research and Aaron Gerlach, Ph.D., Director of Business Development at Icagen explain the challenges and advances in the application of targeted potassium channel openers.
New Generic for Kenalog-40 Approved
Amneal launches only alternative to triamcinolone acetonide injectable.
G-CON on the Road to BIO: Managing Mobility, Flexibility & Risk With Modular Design
Michael Katsis, Director of Business Development and Sidney Backstrom, Executive Director of Business Management at G-CON Manufacturing, Inc.discuss how they provide more of a turnkey solution for customers.
Acoustics for Separation and Filtration of Applications
Stanley Kowalski III, Co-Founder, Chairman & CEO of FloDesign Sonics discusses innovative technology for cell separation.
Creating A Unique Cleanroom, Faster
Jason Dollarhide, President of Cleanroom Constructors Incorporated explains helping clients become more FDA compliant.
Nice Insight Research
Chain Annual Study
- Managing the Complexities of Outbound Clinical Drug Distribution By: Wes Wheeler, Ariette van Strien, Marken
- Segregation in the Design of Gene Therapy Manufacturing Facilities Peter Walters, CRB USA
- Building the Foundation of Japan’s Premier CDMO Jun Yokohama, Bushu Pharmaceuticals Ltd., Toshio Yoshioka, Spera Pharma, Inc.
- Developing Targeted Potassium Channel Openers for CNS-Related Therapeutics Doug Krafte, Ph.D., Neil Castle, Ph.D., Aaron Gerlach, Ph.D., Icagen
- Right-First-Time Innovation Approach Drives Continual Investment Adam Kujath, Alcami
- Achieving Efficient Pharmaceutical Synthesis with Process Intensification Stéphane Laurent, Servier CDMO
- Achieving a High Level of Customer Service Through Lean Quality Management Warren Horton, Avara Pharmaceutical Services
Pharma's Almanac TVView All Video
Road To BIO: Coming Soon To Your Screen
That’s Nice is producing a film based on the Road To BIO, for release in 2017. Watch the teaser trailer to get a taster of all the behind-the-scenes stories, character insights, and what went into the project.
Facility Expansion at Abzena
John Manzello, President, US, Abzena
Attracting Investors and Shortening Development Times
James C. Greenwood, President & CEO, Biotechnology Innovation Organization (BIO)
Providing a Complete Modular Solution
George Wiker, Executive Director, AES
Bringing Bioscience to Space
Bill Goodman, Ph.D., Vice President, SCORPIO-V, a Division of HNu Photonics
Devin Ridgley, Project Scientist, SCORPIO-V, a Division of HNu Photonics
LatestView All Latest
Dec 15, 2017 11:44:03 AM PAO-M12-17-NI-025
Dec 15, 2017 11:40:38 AM PAO-M12-17-NI-024
Dec 15, 2017 11:36:12 AM PAO-M12-17-NI-023
Dec 15, 2017 11:30:34 AM PAO-M12-17-NI-022
Dec 14, 2017 12:37:45 PM PAO-M12-17-NI-021
Dec 14, 2017 12:04:09 PM PAO-M12-17-NI-018
Dec 12, 2017 1:27:27 PM PAO-M12-17-NI-017
Dec 8, 2017 10:36:14 AM PAO-M12-17-NI-013
Dec 8, 2017 10:31:13 AM PAO-M12-17-NI-012
Dec 8, 2017 10:20:38 AM PAO-M12-17-NI-011
Dec 8, 2017 10:17:37 AM PAO-M12-17-NI-010
Dec 7, 2017 3:13:06 PM PAO-M12-17-NI-007
Dec 5, 2017 1:59:20 PM PAO-M12-17-NI-006
TOPICSView All Topics
Dec 15, 2017 9:54:54 AM
Dec 15, 2017 9:50:01 AM
Dec 14, 2017 7:31:19 PM
Dec 14, 2017 6:09:07 PM
Dec 14, 2017 2:15:57 PM
Dec 14, 2017 2:12:12 PM
The contract manufacturing market for antibody-drug conjugates has huge potential, but an extraordinary range of capabilities is essential to be in the game. We spoke to some of the players to find out all about ADCs.
By the Numbers
2017 Top 5 Industry Leaders
Now stronger than ever, Marken needed a bold visual direction to illustrate its expanding breadth of services and ongoing commitment to personalized medicine.
Nice Insight Overview